Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

This study is currently recruiting participants.
Verified February 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Pfizer
GlaxoSmithKline
Information provided by (Responsible Party):
Maryellen Sun, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00749320
First received: September 5, 2008
Last updated: February 13, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)